Efficacy of metronomic capecitabine plus aromatase inhibitor as initial therapy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer: The phase III MECCA trial

被引：0
|
作者：
Wang, S. [1 ]
Hong, R. [2 ]
Xu, F. [2 ]
Xia, W. [2 ]
Teng, Y. [3 ]
Ouyang, Q. [4 ]
Yuan, Z. [2 ]
Jiang, K. [2 ]
Lin, Y. [5 ]
Liu, X. [6 ]
Chen, Q. [7 ]
Wu, X. [8 ]
Shi, Y. [2 ]
Huang, J. [2 ]
An, X. [2 ]
Xue, C. [2 ]
Bi, X. [2 ]
Zheng, Q. [2 ]
Chen, M. [2 ]
Li, H. [9 ]
机构：
[1] Sun Yat Sen Univ Canc Ctr, Med Oncol, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ Canc Ctr, Dept Med Oncol, Guangzhou, Guangdong, Peoples R China
[3] China Med Univ, Hosp 1, Dept Med Oncol, Shenyang, Liaoning, Peoples R China
[4] Hunan Canc Hosp, Dept Breast Canc Med Oncol, Changsha, Peoples R China
[5] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Breast Surg, Guangzhou, Peoples R China
[6] Ningxia Med Univ, Gen Hosp, Dept Med Oncol, Yinchuan, Ningxia, Peoples R China
[7] Guangdong Prov Chinese Med Hosp, Dept Breast, Guangzhou, Peoples R China
[8] Hubei Canc Hosp, Dept Breast, Wuhan, Peoples R China
[9] Sichuan Canc Hosp, Dept Breast Surg, Chengdu, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.319
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
371P
引用
收藏
页码：S374 / S374
页数：1
相关论文
共 50 条
  • [41] Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer
    Burstein, Harold J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (26): : 2557 - 2570
  • [42] Neoadjuvant Therapy for weak receptor-positive/HER2-negative Breast Cancer
    Judith Lorenz, Kuenzell
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (11) : 1124 - 1124
  • [43] Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
    Alessandra Fabi
    Michelangelo Russillo
    Gianluigi Ferretti
    Giulio Metro
    Cecilia Nisticò
    Paola Papaldo
    Ferdinando De Vita
    Giuliana D’Auria
    Antonello Vidiri
    Diana Giannarelli
    Francesco Cognetti
    BMC Cancer, 12
  • [44] Efficacy and clinical outcome of chemotherapy and endocrine therapy as first-line treatment in patients with hormone receptor-positive HER2-negative metastatic breast cancer
    Yuan, Yang
    Zhang, Shaohua
    Wang, Tao
    Bian, Li
    Yan, Min
    Yin, Yongmei
    Song, Yuhua
    Wen, Yi
    Li, Jianbin
    Jiang, Zefei
    CHINESE MEDICAL JOURNAL, 2023, 136 (12) : 1459 - 1467
  • [45] Efficacy and clinical outcome of chemotherapy and endocrine therapy as first-line treatment in patients with hormone receptor-positive HER2-negative metastatic breast cancer
    Yuan Yang
    Zhang Shaohua
    Wang Tao
    Bian Li
    Yan Min
    Yin Yongmei
    Song Yuhua
    Wen Yi
    Li Jianbin
    Jiang Zefei
    中华医学杂志英文版, 2023, 136 (12)
  • [46] Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide in patients with HER2-negative metastatic breast cancer
    Ohtani, S.
    Fujihara, M.
    ANNALS OF ONCOLOGY, 2015, 26 : 30 - 30
  • [47] Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
    Fabi, Alessandra
    Russillo, Michelangelo
    Ferretti, Gianluigi
    Metro, Giulio
    Nistico, Cecilia
    Papaldo, Paola
    De Vita, Ferdinando
    D'Auria, Giuliana
    Vidiri, Antonello
    Giannarelli, Diana
    Cognetti, Francesco
    BMC CANCER, 2012, 12
  • [48] Capecitabine in Combination with Endocrine Therapy as Maintenance Therapy after Bevacizumab Plus Paclitaxel Induction Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: KBCSG-TR1214
    Masuda, Norikazu
    Yoshinami, Tetsuhiro
    Ikeda, Masahiko
    Mizutani, Makiko
    Yamaguchi, Miki
    Komoike, Yoshifumi
    Takashima, Tsutomu
    Yoshidome, Katsuhide
    Tsurutani, Junji
    Iwamoto, Mitsuhiko
    Fujisawa, Fumie
    Yasojima, Hiroyuki
    Yamamura, Jun
    Morishima, Hirotaka
    Aki, Fuminori
    Yamada, Tomomi
    Morita, Satoshi
    Nakayama, Takahiro
    CANCERS, 2021, 13 (17)
  • [49] Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
    Rozenblit, Mariya
    Mun, Sophia
    Soulos, Pamela
    Adelson, Kerin
    Pusztai, Lajos
    Mougalian, Sarah
    BREAST CANCER RESEARCH, 2021, 23 (01)
  • [50] Ribociclib plus endocrine therapy in hormone receptor-positive, HER2-negative advanced breast cancer: A pooled safety analysis
    Burris, H. A.
    Chan, A.
    Im, S-A
    Chia, S.
    Tripathy, D.
    Esteva, F. J.
    Campone, M.
    Bardia, A.
    Kong, O.
    Bao, W.
    Diaz-Padilla, I.
    Lorenc, K. Rodriguez
    Yardley, D. A.
    CANCER RESEARCH, 2019, 79 (04)
12345